Science and Nature news
- News in Brief
- Published: 13 September 2024
volume 42, page 1325 (2024)Cite this article
Voranigo (vorasidenib), made by French drugmaker Servier Pharmaceuticals, was approved in August by the US Food and Drug Administration. The small-molecule isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor has the go-ahead to treat patients with grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations.
The approval follows a successful phase 3 trial showing that Voranigo more than doubled the mean progression-free survival in patients with residual or recurrent grade 2 IDH-mutant glioma after surgery. Patients treated with vorasidenib had a median progression-free survival of 27.7 months, compared with 11.1 months for those receiving a placebo.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Rights and permissionsAbout this article
Cite this article
FDA approves first IDH-targeted glioma drug.
Nat Biotechnol 42, 1325 (2024). https://doi.org/10.1038/s41587-024-02408-8
-
Published: 13 September 2024
-
Issue Date: September 2024
-
DOI: https://doi.org/10.1038/s41587-024-02408-8
